New drug trial aims to shrink enlarged spleens in blood cancer patients
NCT ID NCT05020652
Summary
This study is testing whether a new oral drug called TQ05105 is better than the standard drug hydroxyurea for treating myelofibrosis, a serious bone marrow cancer. It will involve about 107 adults with moderate to high-risk disease. The main goal is to see if the new drug can reduce spleen size by more than 35% after 24 weeks and improve symptoms like fatigue and pain.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE AND HIGH RISK MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, 510055, China
-
Institute of Hematology & Blood Diseases Hostpital, Chinese Academy of medical sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, 300020, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100005, China
-
West China School of Medicine / West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.